Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases.

Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, Rodgers M, McIntyre MQ, Abraham LJ, French MA.

AIDS. 2002 Oct 18;16(15):2043-7.

PMID:
12370503
2.

MHC haplotypes affect the expression of opportunistic infections in HIV patients.

Price P, Keane NM, Stone SF, Cheong KY, French MA.

Hum Immunol. 2001 Feb;62(2):157-64.

PMID:
11182226
3.

Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy.

Price P, Mathiot N, Krueger R, Stone S, Keane NM, French MA.

J Clin Virol. 2001 Oct;22(3):279-87.

PMID:
11564593
4.

Immune restoration disease: a consequence of dysregulated immune responses after HAART.

Stone SF, Price P, French MA.

Curr HIV Res. 2004 Jul;2(3):235-42. Review.

PMID:
15279587
5.

Immune restoration disease after antiretroviral therapy.

French MA, Price P, Stone SF.

AIDS. 2004 Aug 20;18(12):1615-27. Review.

PMID:
15280772
6.
7.

Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART.

French MA.

AIDS Read. 1999 Nov;9(8):548-9, 554-5, 559-62. Review.

PMID:
11082733
8.

The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy.

Jevtović DJ, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O.

HIV Med. 2005 Mar;6(2):140-3.

10.

Proliferation of weakly suppressive regulatory CD4+ T cells is associated with over-active CD4+ T-cell responses in HIV-positive patients with mycobacterial immune restoration disease.

Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S, Marriott D, Pett S, Nanan R, Cooper DA, Zaunders JJ, Kelleher AD.

Eur J Immunol. 2009 Feb;39(2):391-403. doi: 10.1002/eji.200838630.

11.

Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.

de Boer MG, Kroon FP, Kauffmann RH, Vriesendorp R, Zwinderman K, van Dissel JT.

Neth J Med. 2003 Dec;61(12):408-12.

12.

TLR2-induced cytokine responses may characterize HIV-infected patients experiencing mycobacterial immune restoration disease.

Tan DB, Lim A, Yong YK, Ponnampalavanar S, Omar S, Kamarulzaman A, French MA, Price P.

AIDS. 2011 Jul 31;25(12):1455-60. doi: 10.1097/QAD.0b013e328348fb18.

PMID:
21610488
13.

Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis.

Tan DB, Yong YK, Tan HY, Kamarulzaman A, Tan LH, Lim A, James I, French M, Price P.

HIV Med. 2008 May;9(5):307-16. doi: 10.1111/j.1468-1293.2008.00565.x.

14.

Tumor necrosis factor region polymorphisms are associated with AIDS and with cytomegalovirus retinitis.

Deghaide NH, Rodrigues Mde L, Castelli EC, Mendes-Junior CT, Figueiredo JF, Donadi EA.

AIDS. 2009 Aug 24;23(13):1641-7. doi: 10.1097/QAD.0b013e32832e5591.

PMID:
19542865
15.

Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.

Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ.

J Allergy Clin Immunol. 2004 Apr;113(4):742-6.

PMID:
15100682
16.
17.

Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease.

Lim A, D'Orsogna L, Price P, French MA.

AIDS Res Ther. 2008 Apr 29;5:9. doi: 10.1186/1742-6405-5-9.

19.
20.

Spontaneous perforation of the terminal ileum in an AIDS patient on highly active antiretroviral therapy with disseminated non-tuberculous mycobacterial infection.

Kawana M, Starr RS, Tashima KT, Treaba DO, Flanigan TP.

Int J Infect Dis. 2008 Nov;12(6):603-6. doi: 10.1016/j.ijid.2007.12.013. Epub 2008 Apr 22.

Supplemental Content

Support Center